Paper7844593
Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile.
Fields KK and 9 others. J Clin Oncol, 1995. Cited by 76 papers, by iCite.
Cite this record
ConductScience Library. Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile. Papers, record 7844593. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7844593
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics24
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Hematopoietic Stem Cell Transplantation | Major topic |
| Acute Disease | |
| Adolescent | |
| Adult | |
| Aged | |
| Breast Neoplasms | |
| Cisplatin | |
| Drug Tolerance | |
| Etoposide | |
| Female | |
| Germinoma | |
| Hodgkin Disease | |
| Humans | |
| Ifosfamide | |
| Leukemia | |
| Lymphoma, Non-Hodgkin | |
| Male | |
| Middle Aged | |
| Ovarian Neoplasms | |
| Prognosis | |
| Sarcoma | |
| Testicular Neoplasms | |
| Transplantation, Autologous |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| P30CA43703 | NCI NIH HHS | United States | P30CA043703 | PubMed and NIH |
Source NIH RePORTER
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 7602373 | High-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support. | https://conductscience.org/library/papers/7602373 |
Source PubMed
Cited by11
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 76 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 34777885 | The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin's Lymphoma. | Case Rep Hematol | 2021 | https://conductscience.org/library/papers/34777885 | PubMed |
| 33707839 | Conditioning Regimens for Relapsed/Refractory Lymphoma Patients Undergoing Autologous Stem Cell Transplantation: BEAM Versus High Dose ICE. | Indian J Hematol Blood Transfus | 2021 | https://conductscience.org/library/papers/33707839 | PubMed |
| 26377357 | Finding the Optimal Conditioning Regimen for Relapsed/Refractory Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation: A Retrospective Comparison of BEAM and High-Dose ICE. | Turk J Haematol | 2016 | https://conductscience.org/library/papers/26377357 | PubMed |
| 22028494 | Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with autologous stem cell transplant in refractory cancer: pharmacokinetic and pharmacodynamic correlates. | Clin Cancer Res | 2011 | https://conductscience.org/library/papers/22028494 | PubMed |
| 12373594 | Platinum drugs in the treatment of non-small-cell lung cancer. | Br J Cancer | 2002 | https://conductscience.org/library/papers/12373594 | PubMed |
| 12182684 | High-dose chemotherapy and stem cell support for breast cancer: where are we now? | Drugs Aging | 2002 | https://conductscience.org/library/papers/12182684 | PubMed |
| 11710823 | Sequential detection of alphafetoprotein-bearing cells in blood stem cell fraction of germ cell tumour patients. | Br J Cancer | 2001 | https://conductscience.org/library/papers/11710823 | PubMed |
| 11161394 | A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation. | Br J Cancer | 2001 | https://conductscience.org/library/papers/11161394 | PubMed |
| 10745265 | Multi-purpose silastic dual-lumen central venous catheters for both collection and transplantation of hematopoietic progenitor cells. | Bone Marrow Transplant | 2000 | https://conductscience.org/library/papers/10745265 | PubMed |
| 9010989 | Fatigue in women treated with bone marrow transplantation for breast cancer: a comparison with women with no history of cancer. | Support Care Cancer | 1997 | https://conductscience.org/library/papers/9010989 | PubMed |
| 8847558 | Delayed, transient encephalopathy after marrow transplantation: case reports and MRI findings in four patients. | J Neurooncol | 1996 | https://conductscience.org/library/papers/8847558 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/7844593
GET https://conductscience.org/api/papers/v1/7844593/authors